Objective:

To explore the evolving landscape of treatments for ocular surface disease (OSD) and dry eye disease (DED).

Approach:

Key Findings:

• Rephrase for clarity and connection to treatments.

Interpretation:

The complexity of OSD necessitates a tailored approach to treatment, considering the multifactorial nature of the condition and the diverse therapeutic options available.

Limitations:

• Add a point regarding the lack of patient perspectives.

Conclusion:

The future of OSD treatment is promising, with advancements in targeted therapies and delivery systems expected to improve patient outcomes significantly.

Sources:

• TFOS DEWS II Definition and Classification Report
• Prevalence of Diagnosed Dry Eye Disease in the U.S.
• Dry Eye Breakthroughs in the Making
• Anti-evaporative prescription treatment for dry eye disease
• Aldeyra Therapeutics Phase 3 Trial Results
• Dry Eye Disease and Meibomian Gland Dysfunction
• Phase 2b Study of TRPM8 Receptor Agonist
• Alcon Phase 3 COMET Trials Results
Source

Based on findings from:

Ocular Surface Disease Treatments in the Pipeline

Bela Parekh, MD, Jai G. Parekh, MD, MBA, FAAO. Ophthalmology Management, 2025.

https://www.ophthalmologymanagement.com/issues/2025/may/ocular-surface-disease-treatments-in-the-pipeline

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.